Results 171 to 180 of about 47,030 (243)

Treatments for actinic prurigo: A case report with upadacitinib and systematic review. [PDF]

SAGE Open Med Case Rep
Perlmutter JW, Levy R, Sibbald C.
europepmc   +1 more source

Thalidomide combined with ifosfamide significantly improves survival in patients with pulmonary metastatic osteosarcoma. [PDF]

Am J Cancer Res
Liu Y, Wang H, Xiang Z.
europepmc   +1 more source

Type 2 Lepra Reaction with Borderline Lepromatous Leprosy. [PDF]

Dermatol Pract Concept
Chen Q, Liu J.
europepmc   +1 more source

Unicentric Castleman disease with paraneoplastic pemphigus and follicular dendritic cell sarcoma: A case report. [PDF]

Oncol Lett
Li Y, Zeng F, Wang Z, Zhao G, Zhou Q.
europepmc   +1 more source

A case report of Behcet's disease in a child with trisomy 8 and literature review. [PDF]

Front Pediatr
Zhang K, Wei C, Jiang L, Zhao X, Su Q, Qi X, Zhao H, Rong Z.   +7 more
europepmc   +1 more source

Expression of Immune Checkpoints <i>LAG-3</i>, <i>CTLA-4</i>, <i>TIM-3</i>, and <i>PD-1</i> in Beta-Thalassemia Patients Treated Using HbF Augmentation Therapy and Regular Transfusions [PDF]

Turk J Haematol
Khan K, Khan U, Shah A, Shah SMI, Khan Y, Khan MTM, Rani GF.   +6 more
europepmc   +1 more source

In utero exposure to medications and congenital eye anomalies. [PDF]

BMJ Open Ophthalmol
Mairesse R, Lepetit M, Dubucs C, Cifuentes EA, Damase-Michel C, Lacroix I.   +5 more
europepmc   +1 more source

Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders

Chemical Society Reviews, 2022
Progress in strategies aimed at breaking down therapeutic target proteins has led to a paradigm shift in drug discovery. Thalidomide and its derivatives are the only protein degraders currently used in clinical practice.
Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi   +2 more
exaly   +2 more sources